Back to search

Article

The Dearth of Representation in FDA Approved Drug Trials

2024-01-17

Abstract excerpt

The generalizability of data derived from randomized controlled trials is of paramount importance given their utility in the Food & Drug Administration (FDA) drug approval process. An essential part of this process is the inclusion of reliably reported gender, race and ethnicity data in trials that lead to FDA drug approval. Despite previous mandates by the FDA and Clinicaltrials.gov , gender and race-specific dat...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
af639379-5e18-59fa-93b8-24cb7aef9792
DOI
10.1101/2024.01.16.24301376
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
The Dearth of Representation in FDA Approved Drug TrialsDOI 10.1101/2024.01.16.24301376
Select a neighboring publication to make it the new centre.